Viewing Study NCT01697293

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 1:24 AM
Ignite Modification Date: 2026-02-08 @ 12:25 PM
Study NCT ID: NCT01697293
Status: TERMINATED
Last Update Posted: 2020-09-24
First Post: 2012-09-13
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer
Sponsor: Prescient Therapeutics, Ltd.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Breast Adenocarcinoma View
None Estrogen Receptor Positive View
None HER2/Neu Negative View
None Recurrent Breast Carcinoma View
None Stage IIB Breast Cancer View
None Stage IIIA Breast Cancer View
None Stage IIIB Breast Cancer View
None Stage IIIC Breast Cancer View
None Stage IV Breast Cancer View
Keywords: